Development of A Generic Blood Test Based on Gene Signatures To Diagnose Hepatocellular Carcinoma Patients
Not Applicable
- Conditions
- Health Condition 1: C220- Liver cell carcinoma
- Registration Number
- CTRI/2023/10/058191
- Lead Sponsor
- Mohamed Rela
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All patients with a diagnosis of hepatocellular carcinoma on imaging
2. All patients with a suspicion of hepatocellular caricnoma based on imaging or tumour markers (elevated AFP, PIVKA)
3. Patients undergoing surgery (resection or transplant) for hepatocellular carcinoma
4. Patients undergoing palliative care modalities (chemotherapy, immunotherapy, embolisation etc) for hepatocellular carcinoma
Exclusion Criteria
1. Age below 18 years, or above 80 years
2. patients with liver tumors other than hepatocellular carcinoma
3. Patients who refuse to enroll for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the mutational status of HCC patients to prognosticate the tumourTimepoint: 15 days, 1,3,6 months, 1 year, 18 months, 2 years
- Secondary Outcome Measures
Name Time Method To correlate and predict risk of recurrence with existing biomarkers - alpha fetoprotein and PIVKATimepoint: 15 days, 1,3,6 months, 1 year, 18 months, 2 years